Neural Therapeutics Inc. CEO Ian Campbell is answering some of the questions raised by Scientific Advisor Professor David Nutt's recent presentation on the potentially revolutionary untapped effects of psychedelic medicine
Today's questions asks: "How do success rates compare between psychedelic treatments and traditional pharmaceuticals for PTSD?"
The presentation focused on what Professor Nutt describes as the utility of psychedelic compounds and their potential to transform the treatment of mental illness.
Neural Therapeutics is a drug-discovery company focusing on plant-based active substances with the goal of delivering beneficial, over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments where no significant treatment is available today.